Mild cognitive impairment and Alzheimer disease have a low prevalence among newly diagnosed patients with multiple sclerosis.

Ozanimod treatment for early relapsing multiple sclerosis helps prevent impaired cognitive functioning during the first year of use.

Cladribine treatment for relapsing multiple sclerosis improves health-related quality of life and preserves cognitive function after 4 years.

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

Children with pediatric-onset multiple sclerosis (POMS) have shorter telomeres, suggesting MS may accelerate biological aging.

Credit: Getty Images Presenting at ACTRIMS 2025, researchers reported on the safety and clinical efficacy over 24 months of patients with relapsing multiple sclerosis switching to cladribine from ...

Efficacy of treatment is maintained during the switch from IV anti-CD20 therapies to ofatumumab in relapsing MS regardless of race/ethnicity.

Ocrelizumab treatment in Black and Hispanic patients with MS reduces NfL levels and prevents the forming of contrast-enhancing lesions and new or enlarging T2 lesions.